Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Stable regs key to pharma innovation.

Michel and Battalgia 20 – Chief Judge Michel appointed to the United States Court of Appeals for the Federal Circuit in March of 1988 by President Ronald Reagan, an accomplished first-chair trial lawyer, appellate lawyer, and former US Justice Department lawyer who has successfully tried to verdict a broad array of civil and criminal cases, (Paul and John, “Pandemics and the Need for U.S. Patent Laws That ‘Promote … Progress’ and Invention: The Federal Circuit, En Banc, Can Fix This,” IP Watchdog, 4-12-20, https://www.ipwatchdog.com/2020/04/12/pandemics-need-us-patent-laws-promote-progress-invention-federal-circuit-en-banc-can-fix/id=120575/, Accessed 7-4-20, LASA-AH)

Needless to say, no one involved in U.S. patent law or policy wants the pandemic or its multi-faceted consequences. Nor would a contrary ruling in Athena, supra, have meant that an innovator would have had at the ready the desired diagnostic testing for coronavirus. Nor a ready-made or known treatment, cure or vaccine. That said, the famous Burkean wisdom of course applies here. To paraphrase, “evil” or horrendous things can prevail if good people stand by and do nothing—and allowing bad precedents to go uncorrected has consequences. Unfortunately, we are seeing those consequences play out with U.S. patent law in real time. For nearly 15 years, the Supreme Court’s IP opinions that have had the effect of de-valuing U.S. patent rights, making it increasingly difficult (for example) for U.S. intellectual-property owners to obtain injunctive relief against those who infringe, trespass on, or otherwise steal their patented ideas and property rights. See, e.g., eBay Inc. v. MercExchange, LLC, 547 U.S. 388, 391 (2006). (By contrast, the patent laws of China have made such injunctive relief available as a matter of course, with some reporting that prevailing patentees there obtain injunctions for nearly 90% of all requests.) And through the years, whether by Supreme Court precedent or other law-making, it has become increasingly easy to invalidate U.S. patents, see, e.g., KSR Int’l Co. v. Teleflex, Inc., 550 US 398, 415 (2007), and to render the subject matter of a patent ineligible for protection under §101. (We do not tackle here the separate pitfalls created by the 2011 America Invents Act.) This includes ineligibility not just for diagnostic testing, but for software, business methods, and quite possibly anything else in a patent claim that can be subjectively deemed “directed to” an “abstract idea, law of nature, or natural phenomena”; and doesn’t reflect an “inventive concept,” per the Supreme Court’s Mayo-Alice “framework” for Section101. To be sure, this is not an article focused on Supreme Court Section101 precedent and the harms to innovation that it has wrought, though that has certainly played a major or even primary role in the harm to U.S. innovation. (And indeed, the proper analysis of that Section 101 precedent is a subject that warrants separate, in-depth treatment.) The larger point here is that, given the expanding uncertainty with the case law on U.S. patents—and whether, for example, they’ll protect the subject matter of a million- (or even billion-) dollar investment—U.S. investment in R&D has dropped. And perhaps most notably, it has dropped among innovative bio-pharmaceutical companies. See, e.g., Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation, by Christopher M. Holman, 76 Mo. L. Rev. 645, 663-64 (summer 2015) (“In recent years, major innovative pharmaceutical companies have experienced two pronounced and significant trends: a decreasing output of innovative new drugs and cutbacks in research and development (R&D) investment”). And innovation—the lifeblood of the American economy—has dropped with it. See, e.g., id. (explaining that the “high level of unpredictability in today’s patent law is a significant impediment to the development of new medicines” and cause of the “R&D crisis”); Bloomberg Innovation Index (2018); The U.S. Drops out of the Top 10 in Innovation Ranking, Bloomberg News (Jan. 22, 2018), by Michelle Jamrisko & Wei Lu, available at (visited March 28, 2020).

Sign in to recut, update, or save this card.